Melanoma, Malignant Completed Phase 2 Trials for Temozolomide (DB00853)

Also known as: Malignant Melanoma / [M]Malignant melanoma NOS / Melanoma / Melanoma malignant

IndicationStatusPhase
DBCOND0107071 (Melanoma, Malignant)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01704287Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)Treatment
NCT00539591Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk MelanomaTreatment